Dr. William J. Gradishar, MD

Dr. Gradishar practices at Northwestern Medicine Prentice Women's Hospital in Chicago, Illinois.

Dr. Gradishar's NPI, 1437187929, was assigned on June 30, 2006. Dr. Gradishar graduated from University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) in 1982. Dr. Gradishar holds Illinois license 036067208.

Dr. Gradishar's primary practice is Northwestern Medicine Prentice Women's Hospital, at 250 E Superior St, Chicago, IL 60611 in Cook County. The practice phone is (312) 472-3664.

Dr. Gradishar's primary practice is Northwestern Medicine Prentice Women's Hospital in Chicago, Illinois. Dr. Gradishar is also affiliated with Northwestern Memorial Hospital. The medical group on file is Northwestern Medical Faculty Foundation. Dmand AI also links Dr. Gradishar to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gradishar practices, 7 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Gradishar's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Gradishar is licensed in Illinois.

CMS data shows 50,082 Medicare services from Dr. Gradishar across 21 procedure codes in 2024, for 431 Medicare patients. Medicare paid $812,478 for them. Every service was in an office.

CMS counts 431 Medicare patients who saw Dr. Gradishar in 2024. The largest group is 65 to 74, with 214 patients. 75% of them have cancer, and 71% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.40, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Gradishar's median patient age at 67, with 98% women.

In 2024, Dr. Gradishar wrote 687 Medicare Part D claims for 188 patients. 75% of them were for generic drugs. CMS names the drug for 612 of them, across 11 drugs with 11 or more claims each, at $2,260,590 in total drug cost. In 2023, CMS named 500 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Gradishar for performance year 2024, reported through an alternative payment model (APM). Dr. Gradishar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gradishar as offering telehealth.

Dmand AI links 187 papers to Dr. Gradishar, published from 2005 to 2025. 2023 was the busiest year, with 13. The most frequent topics are Breast Neoplasms, Receptor, ErbB-2 and Antineoplastic Agents. Dr. Gradishar has published most often in J Natl Compr Canc Netw. Dr. Gradishar's most frequent co-authors are Massimo Cristofanilli, MD, John H. Ward, MD and Cesar Augusto Santa-Maria, MD.

Dmand AI links Dr. Gradishar to 10 clinical trials, 7 of them phase 3 studies. 7 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Breast Carcinoma In Situ. National Cancer Institute (NCI) sponsors the most, 4. Open Payments lists research payments to Dr. Gradishar that name 1 trial.

CMS Open Payments shows 358 general payments to Dr. Gradishar from 33 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. AstraZeneca Pharmaceuticals LP paid the most, $121,643. It also lists 34 research payments totaling $71,149 from 2016 to 2025, naming 1 clinical trial.

Dr. Gradishar graduated from University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) in 1982.